Product Program year 2025 Source: CMS Open Payments

Paxlovid

Drug Infectious Diseases

NDC 0069-1085-30

Open in the dashboard

General payments

$7,388,348

354,922 payments

Research payments

$75,254,994

4,237 payments

Through program year 2025, $7,388,348 in general payments and $75,254,994 in research payments were reported against Paxlovid (Infectious Diseases).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Amount Payments
2025 General $874,573 24,639
2025 Research $1,572,291 200
2024 General $1,320,442 51,744
2024 Research $3,154,141 351
2023 General $3,682,944 192,061
2023 Research $15,056,516 1,540
2022 General $1,510,388 86,478
2022 Research $55,472,046 2,146

Breakdown

Who paid General payments · program years 2022–2025
  1. Pfizer Inc. $7,282,038 351,462 payments
  2. Array BioPharma Inc. $34,695 2,065 payments
  3. Pfizer International LLC $22,834 5 payments
  4. Pfizer Chile S.A. $20,600 3 payments
  5. PBG Puerto Rico LLC $19,739 988 payments
  6. Hospira, Inc. $8,442 399 payments
Top recipients General payments · program year 2025
  1. Trevor Cummings Emergency Medicine · Grand Rapids, MI $32,829 4% · 10 payments
  2. Teena Chopra Infectious Disease · Detroit, MI $29,840 3% · 7 payments
  3. Ali Hassoun Infectious Disease · Huntsville, AL $29,354 3% · 12 payments
  4. Timothy Connelly Internal Medicine · Savannah, GA $25,721 3% · 19 payments
  5. Christian Sandrock Internal Medicine · Sacramento, CA $21,456 2% · 14 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Internal Medicine $202,779 24% · 3,340 practitioners
  2. Infectious Disease Internal Medicine $140,625 16% · 82 practitioners
  3. Family Medicine $121,724 14% · 3,256 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $78,047 9% · 2,585 practitioners
  5. Emergency Medicine $71,496 8% · 492 practitioners

The top 5 of 133 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Michigan $95,957 11% · 699 recipients
  2. New York $90,468 10% · 1,335 recipients
  3. California $72,953 8% · 1,156 recipients
  4. Pennsylvania $62,860 7% · 899 recipients
  5. Texas $59,740 7% · 1,537 recipients

The top 5 of 52 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

869,861

Prescriptions dispensed, refills included

Drug cost

$43,214,530

Paid at the pharmacy, in all

Medicare Part D drugs matched to PAXLOVID, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Paxlovid Nirmatrelvir/Ritonavir Same name 42,969 855,047 $43,044,382
Paxlovid (Eua) Nirmatrelvir/Ritonavir Similar name 897 14,814 $170,148

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 155 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Bartho Caponi Internal Medicine WI 2,147 $77,239 No profile
Ying Zhang Family Practice CA 1,489 $1,530 None on record
Elif Tokcan - Talegon Internal Medicine CA 992 $2,975 No profile
Christina Carney Nurse Practitioner MN 703 $35,509 No profile
Naziha Hussain Pharmacist CA 692 $493 No profile

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 155 with Patron
354,922 general · 4,237 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record